{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:03:06Z","timestamp":1768345386912,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,2,17]],"date-time":"2009-02-17T00:00:00Z","timestamp":1234828800000},"content-version":"vor","delay-in-days":3731,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[1998,12]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Three subtypes of human (h) arginine vasopressin (AVP) receptors, hV<jats:sub>1A<\/jats:sub>, hV<jats:sub>1B<\/jats:sub> and hV<jats:sub>2<\/jats:sub>, were stably expressed in Chinese hamster ovary (CHO) cells and characterized by [<jats:sup>3<\/jats:sup>H]\u2010AVP binding studies. In addition, the coupling of the expressed receptor protein to a variety of signal transduction pathways was investigated.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Scatchard analysis of saturation isotherms for the specific binding of [<jats:sup>3<\/jats:sup>H]\u2010AVP to membranes, prepared from CHO cells transfected with hV<jats:sub>1A<\/jats:sub>, hV<jats:sub>1B<\/jats:sub> and hV<jats:sub>2<\/jats:sub> receptors, yielded an apparent equilibrium dissociation constant (<jats:italic>K<\/jats:italic><jats:sub>d<\/jats:sub>) of 0.39, 0.25 and 1.21 n<jats:sc>m<\/jats:sc> and a maximum receptor density (<jats:italic>B<\/jats:italic><jats:sub>max<\/jats:sub>) of 1580 fmol mg<jats:sup>\u22121<\/jats:sup> protein, 5230 fmol mg<jats:sup>\u22121<\/jats:sup> protein and 7020 fmol mg<jats:sup>\u22121<\/jats:sup> protein, respectively. Hill coefficients did not differ significantly from unity, suggesting binding to homogenous, non\u2010interacting receptor populations.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Pharmacological characterization of the transfected human AVP receptors was undertaken by measuring the relative ability of nonpeptide AVP receptor antagonists, YM087, OPC\u201021268, OPC\u201031260, SR 49059 and SR 121463A, to inhibit binding of [<jats:sup>3<\/jats:sup>H]\u2010AVP. At hV<jats:sub>1A<\/jats:sub> receptors, the relative order of potency was SR49059&gt;YM087&gt;OPC\u201031260&gt;SR 121463A&gt;&gt;OPC\u201021268 and at hV<jats:sub>2<\/jats:sub> receptors, YM087=SR 121463A&gt;OPC\u201031260&gt;SR 49059&gt;&gt;OPC\u201021268. In contrast, the relative order of potency, at hV<jats:sub>1B<\/jats:sub> receptors, was SR 49059&gt;&gt;SR 121463A=YM087=OPC\u201031260=OPC\u201021268.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In CHO cells expressing either hV<jats:sub>1A<\/jats:sub> or hV<jats:sub>1B<\/jats:sub> receptors, AVP caused a concentration\u2010dependent increase in intracellular Ca<jats:sup>2+<\/jats:sup> concentration ([Ca<jats:sup>2+<\/jats:sup>]<jats:sub>i<\/jats:sub>) with an EC<jats:sub>50<\/jats:sub> value of 1.13 n<jats:sc>m<\/jats:sc> and 0.90 n<jats:sc>m<\/jats:sc>, respectively. In contrast, stimulation of CHO cells expressing hV<jats:sub>2<\/jats:sub> receptors resulted in an accumulation of cyclic AMP with an EC<jats:sub>50<\/jats:sub> value of 2.22 n<jats:sc>m<\/jats:sc>. The potency order of antagonists in inhibiting AVP\u2010induced [Ca<jats:sup>2+<\/jats:sup>]<jats:sub>i<\/jats:sub> or cyclic AMP response was similar to that observed in radioligand binding assays.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In conclusion, we have characterized the pharmacology of human cloned V<jats:sub>1A<\/jats:sub>, V<jats:sub>1B<\/jats:sub> and V<jats:sub>2<\/jats:sub> receptors and used these to determine the affinity, selectivity and potency of nonpeptide AVP receptor antagonists. Thus they may prove to be a valuable tool in further examination of the physiological and pathophysiological roles of AVP.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (1998) <jats:bold>125<\/jats:bold>, 1463\u20131470; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0702220\">10.1038\/sj.bjp.0702220<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0702220","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T19:52:59Z","timestamp":1106941979000},"page":"1463-1470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells"],"prefix":"10.1111","volume":"125","author":[{"given":"Atsuo","family":"Tahara","sequence":"first","affiliation":[]},{"given":"Masayuki","family":"Saito","sequence":"additional","affiliation":[]},{"given":"Toru","family":"Sugimoto","sequence":"additional","affiliation":[]},{"given":"Yuichi","family":"Tomura","sequence":"additional","affiliation":[]},{"given":"Koh\u2010ichi","family":"Wada","sequence":"additional","affiliation":[]},{"given":"Toshiyuki","family":"Kusayama","sequence":"additional","affiliation":[]},{"given":"Junko","family":"Tsukada","sequence":"additional","affiliation":[]},{"given":"Noe","family":"Ishii","sequence":"additional","affiliation":[]},{"given":"Takeyuki","family":"Yatsu","sequence":"additional","affiliation":[]},{"given":"Wataru","family":"Uchida","sequence":"additional","affiliation":[]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2009,2,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/357333a0"},{"key":"e_1_2_5_3_1","first-page":"1006","article-title":"Structural requirements for activation of vasopressin\u2010sensitive adenylate cyclase, hormone binding, and antidiuretic actions","volume":"14","author":"Butlen D.","year":"1978","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.207"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.137.9.3906"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)83641-4"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.3.7867583"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2760189"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1989.tb08384.x"},{"key":"e_1_2_5_11_1","first-page":"171","article-title":"Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis","volume":"30","author":"Jard S.","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_5_12_1","first-page":"F41","article-title":"Vasopressin receptors from cultured mesangial cells resemble Vla type","volume":"253","author":"Jard S.","year":"1987","journal-title":"Am. J. Physiol."},{"key":"e_1_2_5_13_1","first-page":"73","article-title":"Pharmacology and clinical perspectives of vasopressin antagonists","volume":"43","author":"Laszlo F.A.","year":"1991","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_5_14_1","first-page":"E1095","article-title":"Effect of Avp and oxytocin on insulin release: involvement of Vlb receptors","volume":"269","author":"Lee B.","year":"1995","journal-title":"Am. J. Physiol."},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/bst0070861"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/18.17.5322"},{"key":"e_1_2_5_17_1","first-page":"H2245","article-title":"Effects of oral Avp receptor antagonists Opc\u201021268 and Opc\u201031260 on congestive heart failure in conscious dogs","volume":"267","author":"Naitoh M.","year":"1994","journal-title":"Am. J. Physiol."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199602000-00015"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90524-S"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-126-3-1478"},{"key":"e_1_2_5_21_1","first-page":"H404","article-title":"Effect of Sr\u201049059, a vasopressin Vla antagonist, on human vascular smooth muscle cells","volume":"268","author":"Serradeil\u2010Le Gal C.","year":"1995","journal-title":"Am. J. Physiol."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119098"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116554"},{"key":"e_1_2_5_24_1","doi-asserted-by":"crossref","first-page":"27088","DOI":"10.1016\/S0021-9258(18)47129-3","article-title":"Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor","volume":"269","author":"Sugimoto T.","year":"1994","journal-title":"J. Biol. Chem."},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199712000-00010"},{"key":"e_1_2_5_26_1","first-page":"301","article-title":"Pharmacological profile of Ym087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara A.","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00324-6"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a122662"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)94177-Y"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(92)90067-5"},{"key":"e_1_2_5_31_1","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1016\/S0021-9258(17)41863-1","article-title":"Molecular cloning, sequencing, and functional expression of a cDNA encoding the human Vla vasopressin receptor","volume":"269","author":"Thibonnier M.","year":"1994","journal-title":"J. Biol. Chem."},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112179"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7455701"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1850553"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09058.x"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00940-5"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702220","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0702220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0702220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T21:32:22Z","timestamp":1698528742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0702220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1038\/sj.bjp.0702220"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0702220","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]},"assertion":[{"value":"2009-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}